Follow The Filings

QURE Uniqure NV

Health Care, filed as UNIQURE NV (SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.4%
  • $43M
  • 1 add 1 exit

In 2026 Q2 Lee Ainslie added to Uniqure, while Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Lee Ainslie, Maverick Capital). Not free-float ownership.

  1. Lee Ainslie Add 0.38%

Who owns QURE

Sorted by value, long equity only, as of 2026 Q2.

History
Lee Ainslie, Maverick Capital 0.38%, was 0.14% Add +32.6% 925,383 $43M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 14,000 $229K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by QURE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All QURE insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $19.7M sold by 5 insiders under 10b5-1 plans
  1. Matthew C Kapusta CEO, Managing Director
    Planned sale
    $952K 21,082 shares at $45.16 3.9% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  2. Walid Abi-Saab Chief Medical Officer
    Planned sale
    $1.4M 30,000 shares at $46.42 17% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  3. Jack Kaye Director
    Planned sale
    $983K 21,167 shares at $46.44 45% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  4. Matthew C Kapusta CEO, Managing Director
    Planned sale
    $1.8M 35,412 shares at $50.02 6.4% of stake
    Traded Jun 24–25 Filed Jun 26
    ↗
  5. Matthew C Kapusta CEO, Managing Director
    Planned sale
    $9.4M 206,100 shares at $45.47 28% of stake
    Traded Jun 17–18 Filed Jun 22
    ↗
  6. Madhavan Balachandran Director
    Planned sale
    $526K 11,685 shares at $45.06 21% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  7. Jack Kaye Director
    Planned sale
    $225K 5,295 shares at $42.57 17% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  8. Madhavan Balachandran Director
    Planned sale
    $279K 10,000 shares at $27.85 19% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  9. Robert Gut Director
    Planned sale
    $197K 7,552 shares at $26.05 22% of stake
    Traded Jun 10 Filed Jun 12
    ↗
  10. Jack Kaye Director
    Planned sale
    $79K 2,645 shares at $30.01 12% of stake
    Traded Jun 3 Filed Jun 5
    ↗
  11. Walid Abi-Saab Chief Medical Officer
    Planned sale
    $1.1M 45,000 shares at $25.06 21% of stake
    Traded May 8 Filed May 12
    ↗
  12. Robert Gut Director
    Planned sale
    $630K 25,613 shares at $24.62 44% of stake
    Traded Jan 12 Filed Jan 14
    ↗
  13. Jack Kaye Director
    Planned sale
    $174K 6,390 shares at $27.28 24% of stake
    Traded Jan 9 Filed Jan 12
    ↗
  14. Robert Gut Director
    Planned sale
    $857K 31,434 shares at $27.26 44% of stake
    Traded Nov 6, 2025 Filed Nov 10, 2025
    ↗
  15. Jack Kaye Director
    Planned sale
    $1.2M 38,810 shares at $30.34 66% of stake
    Traded Nov 4, 2025 Filed Nov 6, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 option exercises, 20 sales to cover taxes, and 12 stock grants.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income — — -$198.97M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $651.85M $390.29M $655.99M
Total non-current assets $179.84M $166.25M $168.92M
Total assets $831.69M $556.54M $824.91M
Total current liabilities $73.68M $40.05M $62.92M
Total non-current liabilities $550.34M $523.24M $563.09M
Total equity $207.67M -$6.75M $198.9M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$145.93M -$182.73M -$177.96M
Cash from investing -$205.69M $162.97M -$321.62M
Cash from financing $362.72M -$59.49M $415.4M
Net change in cash $13.37M -$84.22M -$78.53M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.